Among 32 pharma and biotech companies surveyed, structure-based drug design is the most prevalent activity with the most players emphasizing the fragment-based variation.
FACT:
WHAT’S NEW THIS YEAR:
May 21 - 22, 2014 | Westin Boston Waterfront | Boston, MA
Structure-Based Drug DesignUsing Structure and Rational Design to Accelerate Discovery
Fourteenth Annual
FACTS & FIGURESDrug Discovery
PRSRT STD US POSTAGE PAID PERMIT NO. 6HUDSON, MA
CAMBRIDGE HEALTHTECH INSTITUTE250 First Avenue | Suite 300Needham, MA 02494
Hear case studies from:• Arena Pharmaceuticals
• Astex
• AstraZeneca
• Bristol-Myers Squibb
• Carmolex
• Carmot Therapeutics
• Constellation Pharmaceuticals
• Genentech
• Heptares Therapeutics UK
• Merck
• Novartis
• Structural Genomics Consortium
• Takeda
• Vernalis, Ltd.
• Coverage of novel targets and compounds including macrocycles, epigenetic targets, and BACE inhibitors
• Case studies and experimental follow up - see how Constellation, Heptares, AstraZeneca, and others are leading the SBDD charge
• Expanded sessions on GPCR design and drug discovery
• Showcase of different approaches for working with the similar targets
Structure-Based Drug DesignUsing Structure and Rational Design to Accelerate Discovery
Fourteenth Annual
CONSIDER THISThe average cost of bringing a new drug to market is $1.3 billion
FACT:Fewer than 1 in 10 medicines that start being tested in human clinical trials will succeedIn 2012 the FDA approved
39 new drugs
FACT:
FACT:
Enzymes 47%Other Receptors 4%Integrins 1%
DNA 1%Miscellaneous 2%
GPCRs 30%
Ion Channels 7%
Nuclear Hormone Receptors and
Transporters 8%
Current Drug Target Breakdown
The pharmaceutical market will reach nearly
USD by 2016
FACT:$1,200,000,000,000
Structure-Based Drug Designconference help to advance the drug discovery field?
How will CHI’s 14th Annual
By addressing topics that matter:
Executive
Director
Manager
Professor
Scientist/Technologist
Sales & Marketing
Other
11%
12%
8%
12%
46%
6%
5%
USA
Europe
Asia
ROW
60%
25%
10%
5%
Computational Chemistry
Medicinal Chemistry
Drug Discovery
Discovery Technologies
Structural Biology
Structural Chemistry
Biochemistry
Molecular Modeling
Other
15%
17%
13%
6%
9%
13%
11%
5%
11%
Academic
Biotech
Government/ Research Institutions
Pharmaceutical
24%
41%
3%
32%
Attendee Profile
By bringing together industry leaders:
Title
Region
Function
Company Type
Keynote Speaker Chas Bountra, Ph.D., Professor, Translational Medicine, Department of Clinical Medicine; Associate Head, Medical Sciences; Chief Scientist, Structural Genomics Consortium, University of Oxford
Sources: Forbes, Insight Pharma Reports: Medicinal Chemistry, FDA.gov
Register and View Full Details:healthtech.com/structure-based-drug-design
Register by February 28 and Save up to $400!Mention keycode “INW” when registering
GPCRs
New techniques and strategies
Novel targets and compounds
25%
50%
45%
